Automated And Closed Cell Therapy Processing Systems Market to Grow with a CAGR of 9.37% through 2030
Rising investments, regulatory support, and expanding
clinical applications are expected to drive the Global Automated And Closed
Cell Therapy Processing Systems Market growth in the forecast period,
2026-2030.
According to TechSci Research report, “Automated
And Closed Cell Therapy Processing Systems Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2030”, the
Global Automated And Closed Cell Therapy Processing Systems Market stood at USD
931.08 Million in 2024 and is expected to reach USD 1597.30 Million by 2030
with a CAGR of 9.37% during the forecast period. This can be attributed to expanding clinical
applications. Cell therapies are no longer limited to a few niche applications.
They are increasingly being explored for a broader range of clinical
conditions. As the number of clinical trials and approved therapies continues
to grow, so does the demand for automated and closed cell therapy processing
systems. These systems enable the efficient and scalable production of diverse
cell therapy products, catering to a wide spectrum of medical needs.
Furthermore, collaborations and partnerships between
academic institutions, biotechnology companies, and healthcare providers are on
the rise. These collaborations facilitate knowledge sharing, resource pooling,
and accelerated development of cell therapy technologies. Expect to see more
joint ventures aimed at advancing automation in cell therapy manufacturing.
The global pharmaceutical industry has greatly
benefited from the integration of automation into cell therapy processing and
manufacturing systems. These systems play a crucial role in selecting,
isolating, modifying, and expanding cells as part of the manufacturing process
for cell therapies. In this intricate process, even a minor error can lead to
incorrect cell infusion. However, automated and enclosed cell therapy
processing methods significantly reduce the risk associated with the final
product. Automation in cell therapy processing also mitigates the risk of
contamination that can result from manual labor. By reducing the possibility of
errors during bioprocessing, automated and enclosed cell treatment processing
systems enhance the efficiency of cell operations.
The rising global prevalence of cancer has driven the
demand for automated and enclosed cell therapeutic processing systems.
According to the Global Cancer Observatory study, Europe saw an estimated 4.39
million new cancer cases in 2020. Fully automated cell therapy processing
systems are designed to enable robust processing for diseases that are often
considered incurable. Leading companies in the global market are contributing
to this expansion by offering advanced platforms for the cell therapy manufacturing
process. In recent years, there has been substantial growth in clinical trials
related to advanced therapies, which has led to an increased need for advanced
and automated technologies to achieve high throughput and yield. This is
because automated and enclosed systems offer superior cell handling
capabilities and minimize the potential for errors during bioprocessing.
The availability of a range of systems offering both
fully automated integrated workflow solutions and partial automation is
expected to drive adoption in this field. Additionally, these systems enable
continuous monitoring of controlled therapy processing, which is crucial for
the development of new therapeutic platforms. Furthermore, integrated
intelligent algorithms ensure high precision in the process. Market players are
actively involved in developing infrastructure to support the production of
automated systems. For example, in June 2021, Lonza and Cell Point announced
their collaboration to utilize the Cocoon platform for the development of
T-cell-based therapies, aiming to demonstrate a proof of concept for
Point-of-Care (POC) production to optimize supply chain operations. As
automated systems can also enhance analytical testing and facilitate quality
control, their acceptance is expected to grow during the forecast period.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Automated And Closed Cell Therapy Processing Systems Market.”
The Global Automated And Closed Cell Therapy
Processing Systems Market is segmented into workflow, type, scale, regional
distribution, and company.
Based on Scale,
the pre-commercial/R&D scale is currently dominating. This phase is
essential for the development and optimization of cell therapies, where precise
control over the manufacturing process is crucial. Automated and closed systems
are highly valued during early-stage clinical trials and research, as they
provide controlled environments that minimize human intervention, ensuring
consistency and preventing contamination. These systems support the refinement
of cell therapies, maintaining cell integrity and ensuring high-quality
outcomes for proof-of-concept studies. The focus on innovation and research,
coupled with the growing need for precision in early development stages, has
led to the pre-commercial scale taking the lead in the market, although the
commercial scale is expected to grow significantly as therapies advance toward
larger production levels.
Based on region, Asia-Pacific
is the second dominant market, following Europe. This region is witnessing
rapid growth due to several factors that are driving the adoption of automated
and closed systems for cell therapy manufacturing. One of the primary factors
contributing to Asia-Pacific's growing market share is the increasing
investment in healthcare infrastructure and biotechnology. Countries like
China, Japan, India, and South Korea are heavily investing in the development
of advanced healthcare systems, with a particular focus on regenerative
medicine and cell therapy. These investments have spurred the need for
efficient and scalable manufacturing solutions, making automated and closed
cell therapy processing systems a key enabler in meeting this demand. The shift
toward automation in these countries helps address labor shortages, improve
production efficiency, and meet regulatory standards, particularly as the
demand for personalized and cell-based therapies rises.
Asia-Pacific is home to a rapidly expanding biotechnology industry, with many
companies in the region focusing on research, clinical trials, and early-stage
commercialization of cell therapies. The region's increasing number of biotech
startups and research organizations is driving the demand for automated and
closed systems that can support small-scale production while maintaining the
integrity and safety of cell therapies. These systems are critical in
optimizing the manufacturing process during early clinical trials, allowing for
the efficient production of high-quality cell therapies that can be scaled as
these therapies move toward commercial production.
Major companies operating in Global Automated And
Closed Cell Therapy Processing Systems Market are:
- Miltenyi Biotec B.V. & Co. KG
- Lonza Group AG
- Fresenius Kabi AG
- Global Life Sciences Solutions USA LLC
- BioSpherix, LLC
- Terumo Corp
- Sartorius AG
- ThermoGenesis Holdings Inc
- Cellares Corporation
- Thermo Fisher Scientific Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global automated and closed cell therapy
processing systems market is on the brink of transformative change, with the
key trends driving innovation, efficiency, and safety. AI and machine learning,
miniaturization, advanced sensors, closed systems, single-use bioreactors,
decentralized manufacturing, personalized medicine, collaborations, and
regulatory advancements are all poised to shape the future of this dynamic
industry. As these trends continue to unfold, the potential for life-changing
cell therapies to reach patients around the world grows ever closer, promising
a brighter future for healthcare”, said Mr. Karan Chechi, Research Director, TechSci Research, a research-based management consulting firm.
“Automated And Closed Cell Therapy Processing Systems Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented
By Workflow (Separation, Expansion, Apheresis, Fill-Finish, Cryopreservation,
Others), By Type (Stem Cell Therapy, Non-Stem Cell Therapy), By Scale
(Pre-commercial/ R&D Scale, Commercial Scale), By Region and Competition,
2020-2030F”, has evaluated the future growth potential of Global
Automated And Closed Cell Therapy Processing Systems Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Automated And Closed Cell Therapy
Processing Systems Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com